Our real-world data on cardiovascular care is collected from electronic primary and secondary care records. Our cardiovascular disease cohorts contain detailed data from 2002 onwards and are regularly updated and expanded to include new patients.
The cardiovascular risk management program in the Netherlands focuses on the identification, diagnosis and treatment of patients with (increased risk of) cardiovascular disease. The general practitioner is the gatekeeper in the Dutch healthcare system and plays a central role in the cardiovascular risk management (CVRM) program both by direct patient care and referral to other professionals in primary or secondary care. Cardiovascular care is registered in detail in the primary care record, which results in high levels of completeness and quality of our data from the GP Database. The type of data collected include major adverse cardiovascular events (MACE) that resulted in hospitalisations, but also peripheral arterial disease for which patients are often not hospitalised, such as heart failure or intermittent claudication. Clinical parameters collected in the CVRM program include lipid tests, blood pressure, ankle-arm index, BMI, lifestyle (such as exercise, smoking, alcohol consumption and diet), renal function and thyroid function tests.
Besides the GP Database, cardiovascular data is available in the Out-patient Pharmacy Database (drug prescriptions from primary and secondary care), the In-patient Pharmacy Database (drug administration during hospital admission), the Clinical Laboratory Database (tests and results ordered in primary and secondary care) and the Hospitalisation Database (hospital discharge diagnoses and in-hospital procedures). These databases are linked on a patient-level in order to construct the patient journey.
One example of our abilities with these (linked) data is creating insight in lipid modifying treatment effectiveness (see figure).
Examples of studies performed with our cardiovascular data include observational research on drug utilisation, adherence and persistence, generic substitution, intermediate outcome effectiveness (lipid or blood pressure lowering), hard outcome effectiveness (MACE), safety outcomes and healthcare resource utilisation.
Our cohorts are tailor-made and we can collect additional patient-centric data through linkage with external disease-specific registries or collecting patient reported outcomes (PRO).